Edwin Stone

Overview

CEO of Cellular Origins, focused on physical, fluidic, and digital instrument integration to replace unscalable human intermediaries in cell therapy manufacturing, advocating a capital-efficient scale strategy gated on clinical proof. Edwin Stone leads Cellular Origins, a company addressing the cell therapy manufacturing connectivity gap by enabling instrument integration physically through consumable movement, fluidically through sterile connections, and digitally — replacing the armies of people currently performing manual transfer steps between instruments. Stone argues that the cell therapy industry must adopt a capital-efficient strategy for scale: demonstrate clinical proof first before investing heavily in manufacturing platforms and analytics infrastructure, because the industry's track record shows that therapeutics with high clinical risk profiles will always make premature manufacturing investment speculative. (Segment 4 (15:00-20:00))